Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 02 2022 - 7:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
June 2, 2022
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On June 2, 2022, Immatics N.V. (the “Company”
or “Immatics”) announced an expansion of its strategic alliance with Bristol Myers Squibb to pursue the development of multiple
allogeneic off-the-shelf TCR-T and/or CAR-T programs. Under this collaboration, Bristol Myers Squibb and Immatics will develop two programs
owned by Bristol Myers Squibb and both companies have an option to develop up to four additional programs each. The programs will utilize
Immatics’ proprietary gamma delta T cell-derived, allogeneic Adoptive Cell Therapy (ACT) platform, called ACTallo®,
and a suite of next-generation technologies developed by Bristol Myers Squibb. Under the terms of this agreement, Immatics will receive
an upfront payment of $60 million as well as up to $700 million per Bristol Myers Squibb program through development, regulatory and commercial
milestone payments and tiered royalty payments of up to low double-digit percentages on net product sales. Immatics will be responsible
for preclinical development of the initial two Bristol Myers Squibb-owned programs and will receive additional payment for certain activities
that Immatics could perform at Bristol Myers Squibb’s request. Bristol Myers Squibb will assume responsibility for clinical development
and commercialization activities of all Bristol Myers Squibb-owned programs thereafter. In addition, Bristol Myers Squibb and Immatics
will expand their 2019 collaboration agreement focused on autologous T cell receptor-based therapy (TCR-T), with the inclusion of one
additional TCR target discovered by Immatics. As part of this expansion, Immatics will receive an upfront payment of $20 million and be
eligible for milestone payments and royalties.
In connection with the foregoing, the Company issued
a press release, a copy of which is attached hereto as Exhibit 99.1.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than Exhibit 99.1)
shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351 and 333-240260) of
Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished.
EXHIBIT INDEX
Exhibit No. |
Description |
99.1 |
Press release dated June 2, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
IMMATICS N.V. |
|
|
Date: June 2, 2022 |
|
|
By: |
/s/ Harpreet Singh |
|
Name: |
Harpreet Singh |
|
Title: |
Chief Executive Officer |
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024